315 related articles for article (PubMed ID: 10924972)
1. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04.
Murray KJ; Scott C; Zachariah B; Michalski JM; Demas W; Vora NL; Whitton A; Movsas B
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):59-64. PubMed ID: 10924972
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04.
Regine WF; Scott C; Murray K; Curran W
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):711-7. PubMed ID: 11597813
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
Nieder C; Nestle U; Motaref B; Walter K; Niewald M; Schnabel K
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):297-302. PubMed ID: 10661335
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
7. Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.
Bauman G; Yartsev S; Roberge D; MacRae R; Roa W; Panet-Raymond V; Masucci L; Yaremko B; D'Souza D; Palma D; Sexton T; Yu E; Pantarotto JR; Ahmad B; Fisher B; Dar AR; Lambert C; Pond G; Stitt L; Tay KY; Rodrigues G
J Neurooncol; 2016 Jul; 128(3):431-6. PubMed ID: 27084705
[TBL] [Abstract][Full Text] [Related]
8. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
9. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases.
Nieder C; Andratschke N; Grosu AL; Molls M
Strahlenther Onkol; 2003 Jan; 179(1):16-20. PubMed ID: 12540980
[TBL] [Abstract][Full Text] [Related]
10. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.
Rades D; Bohlen G; Dunst J; Lohynska R; Veninga T; Stalpers L; Schild SE; Dahm-Daphi J
Strahlenther Onkol; 2008 Jan; 184(1):30-5. PubMed ID: 18188520
[TBL] [Abstract][Full Text] [Related]
11. Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP).
Rades D; Bohlen G; Lohynska R; Veninga T; Stalpers LJ; Schild SE; Dunst J
Strahlenther Onkol; 2007 Nov; 183(11):631-6. PubMed ID: 17960339
[TBL] [Abstract][Full Text] [Related]
12. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
13. Treatment of five or more brain metastases with stereotactic radiosurgery.
Hunter GK; Suh JH; Reuther AM; Vogelbaum MA; Barnett GH; Angelov L; Weil RJ; Neyman G; Chao ST
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1394-8. PubMed ID: 22209150
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site.
Golden DW; Lamborn KR; McDermott MW; Kunwar S; Wara WM; Nakamura JL; Sneed PK
J Neurosurg; 2008 Dec; 109 Suppl():77-86. PubMed ID: 19123892
[TBL] [Abstract][Full Text] [Related]
15. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.
Gaspar LE; Scott C; Murray K; Curran W
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1001-6. PubMed ID: 10863071
[TBL] [Abstract][Full Text] [Related]
16. Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy?
Hasegawa T; Kondziolka D; Flickinger JC; Germanwala A; Lunsford LD
Neurosurgery; 2003 Jun; 52(6):1318-26; discussion 1326. PubMed ID: 12762877
[TBL] [Abstract][Full Text] [Related]
17. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.
Chidel MA; Suh JH; Reddy CA; Chao ST; Lundbeck MF; Barnett GH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):993-9. PubMed ID: 10863070
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
[TBL] [Abstract][Full Text] [Related]
19. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder.
Rades D; Meyners T; Veninga T; Stalpers LJ; Schild SE
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):404-8. PubMed ID: 20171794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
